No Data
Xiaofang Pharmaceutical (603207.SH): Plans to promote a restricted stock incentive plan of no more than 1.6 million shares.
On January 3, Glory Investment announced that Xiaofang Pharmaceutical (603207.SH) has unveiled a restrictive Stocks incentive plan for 2025, proposing a total of no more than 1.6 million Stocks to be granted, accounting for 1.00% of the company's total share capital of 160 million Stocks at the time of the announcement of the plan. The number of incentive recipients in the initial grant will not exceed 178 people, and the grant price of the initial restrictive Stocks is set at 14.97 yuan per share.
Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHSE:603207) Shares Fly 29% But Investors Aren't Buying For Growth
Xiaofang Pharmaceutical: Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Shanghai Xiaofang Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Xiaofang Pharmaceutical (603207.SH): The net income in the first three quarters was 0.162 billion yuan, a 4.07% decrease compared to the same period last year.
GeLongHui October 28th | Xiao Fang Pharmaceuticals (603207.SH) announced the third quarter report of 2024, with a revenue of 0.367 billion yuan for the first three quarters, a year-on-year increase of 0.05%; net income attributable to shareholders of the listed company was 0.162 billion yuan, a year-on-year decrease of 4.07%; and basic earnings per share was 1.28 yuan.
Xiaofang Pharmaceutical (603207.SH): The company does not produce snake medicine.
On September 9, Gelonghui reported that Xiaofang Pharmaceutical (603207.SH) stated on the interactive platform that the company does not have snake medicine.
